Alternative RNA splicing: contribution to pain and potential therapeutic strategy  by Donaldson, Lucy F. & Beazley-Long, Nicholas
R
ev
ie
w
s
 K
E
Y
N
O
T
E
R
E
V
IE
WDrug Discovery Today  Volume 21, Number 11 November 2016 REVIEWS
Teaser The control of alternative splicing is a growing area of investigation for potential
therapy. Here we consider what is known about alternative splicing and its control in
relation to pain.
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Since the sequencing of metazoan genomes began, it has become clear that
the number of expressed proteins far exceeds the number of genes. It is
now estimated that more than 98% of human genes give rise to multiple
proteins through alternative pre-mRNA splicing. In this review, we
highlight the known alternative splice variants of many channels,
receptors, and growth factors that are important in nociception and pain.
Recently, pharmacological control of alternative splicing has been
proposed as potential therapy in cancer, wet age-related macular
degeneration, retroviral infections, and pain. Thus, we also consider the
effects that known splice variants of molecules key to nociception/pain
have on nociceptive processing and/or analgesic action, and the potential
for control of alternative pre-mRNA splicing as a novel analgesic strategy.
Introduction
The first description of alternative splicing relating specifically to nociceptive systems was the
production of calcitonin gene-related peptide (CGRP) encoded by the calcitonin gene [1], a
neuropeptide intimately associated with nociception and inflammation. Since then, multiple
molecules have been identified in which alternative splice variants might contribute to the
regulation or modulation of nociception, and a limited number have received a great deal of
attention. Unfortunately, despite identification of alternatively spliced isoforms of key molecules
in nociception, such as ion channels, G-protein-coupled receptors (GPCR), or growth factors, how
splicing affects function in the nociceptive system is largely unknown. Inadequate tools to
investigate functional changes, for example antibodies and pharmacological agents that do not
distinguish between splice isoforms, hinder these investigations. Despite the technical hin-
drances, it is known that alternative splicing of, for example, GPCR pre-mRNA, can alter receptor
pharmacology by affecting ligand specificity and potency [2], receptor trafficking and inter-
nalisation [3], and regional and cellular expression [4,5]. Ion channels are fundamental to the
function of nociceptive neurons. They regulate neuronal excitability, neurotransmitter release,
and control sensory transduction at peripheral nociceptive terminals [6]. Many ion channel
families comprise multimers of different subunits, including pore-forming units, and, in some
cases, accessory units. Therefore, there is enormous scope for alternative splicing to modulate
channel function, and pharmacology, and thereby affect pain.
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mechanism through which intronic RNA is removed from the pre-
mRNA and the exons are joined in the mature mRNA. It differs
from constitutive splicing in that alternative exons might or might
not be included, and there may be exon skipping, intron retention,
alternative 50 and 30 splice sites and mutually exclusive exons [7]
(Fig. 1), leading to the generation of potentially hundreds of
proteins from a single mRNA. In some instances, multiple mRNAs1 2 3 4(a)
1 2 3 4(b)
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FIGURE 1
Different types of alternative splicing compared with constitutive splicing. (a)
Genomic structure showing the constitutive splicing of a pre-mRNA
containing four exons, coloured boxes denote different exons. Alternative
splice variants can arise by different mechanisms, such as: (b) exon skipping.
Exon 2 is spliced out of the pre-mRNA; (c) intron retention. The intron
between exons 3 and 4 (yellow) is not spliced out (dotted line) and is included
in the mature mRNA; (d) alternative 50 donor site. An intra-exonic splice site in
exon 1 is used and gives an alternative 50 sequence; (e) alternative 30 acceptor
site. An intra-exonic splice site is used in exon 4 and gives an alternative 30
sequence; (f) alternative promoters; (g) mutually exclusive exons, where two
mature mRNAs exist containing either exon 2 or exon 3 but never both exons
together; (h) alternative polyadenylation sites; or (i) alternative stop codon
use. Top stop codon: Constitutive splicing leads to use of stop codon in exon
4. Bottom stop codon: Exclusion of exon 2 leads to alternative stop codon in
exon 3 and nonsense-mediated decay.
1788 www.drugdiscoverytoday.comare generated that all lead to the translation of the same protein
product, for example brain-derived neurotrophic factor (BDNF)
[8]. Functionally, expression of alternative splice variants can
contribute tissue-specific expression patterns (e.g., BDNF), can
alter neuronal mechanisms, such as neurotransmitter release
(e.g., voltage-gated calcium channels; VGCC), or modulate cellu-
lar survival or function (e.g., neurotrophic factors). Relatively
subtle changes in protein structure brought about through alter-
native splicing can dramatically alter function; for example, pro-
and antiangiogenic forms of vascular endothelial growth factor
that differ in only six amino acids.
Alternative splicing is only one mechanism through which gene
expression is controlled, but it is an important one. This process
must be extremely precise, because splicing at sites even one nucle-
otide out of place can result in shifts in the open reading frame,
production of nonfunctional or aberrant proteins, or unstable
transcripts through the introduction of premature stop codons
leading to nonsense-mediated decay [9]. Given the required preci-
sion of alternative splicing, it is perhaps unsurprising that it is
estimated that up to 50% of disease-causing mutations in the
human genome affect splicing [9,10]. To achieve precision, the
spliceosome, a complex of approximately 170 RNA-binding pro-
teins and small nuclear RNAs in complex forming small nuclear
ribonucleoproteins (snRNPs), must accurately recognise intron and/
or exon boundaries through recognition of specific splicing
sequences [10].
The precise understanding of the alternative splicing mecha-
nisms of specific genes is fairly limited. General mechanisms that
are understood include the presence of other splicing regulatory
proteins, such as the serine-arginine-rich (SR) family of kinases,
and heterogeneous nucleoribonuclear proteins [11]. Tissue-specif-
ic expression of splicing factors, such as Nova1 and 2, or Fox
proteins, adds further complexity to the control of alternative
splicing and RNA maturation. Nova proteins are, for example,
particularly important in the regulation of RNAs contributing to
synaptic function [12].
In this review, we consider what is known about alternatively
spliced variants of GPCRs (particularly mu opioid receptors), ion
channels (particularly VGCCs), and growth factors, for which evi-
dence supports or suggests a contribution to nociceptive proces-
sing. We also speculate briefly on the effects that known splice
variants of key molecules might have on nociception where no
investigations have yet been published. Finally, we consider wheth-
er the control of alternative splicing is a potential analgesic target.
GPCRs, alternative splice variants, and pain
Bioinformatic studies indicate that approximately 50% of GPCRs
are intronless and the remainder can undergo alternative splicing
[13]. For most identified alternatively spliced isoforms, it is not
known how the change of mRNA and, therefore, protein sequence
affects receptor function, because most information derives from
RT-PCR mRNA rather than from functional studies. The question
of how alternative splicing of nociception-associated GPCRs
affects pain and analgesia remains.
Mu (m) opioid receptors
Opioid receptor agonists, such as morphine, mimic the
action of endogenous opioids (encephalin, dynorphins, and
Drug Discovery Today  Volume 21, Number 11 November 2016 REVIEWS
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ion channel function, for example through the inhibition of
VGCCs [14], or activation of G-protein-coupled inwardly rectify-
ing potassium channels [15]. Although opiates are widely used
analgesics, not all patients in need of pain relief respond in the
same manner to these drugs. Patients can be insensitive, develop
tolerance, or suffer adverse effects, such as nausea and vomiting, to
one opiate yet respond effectively to another. Response to opiates
has a clear genetic component because, for example, CXBK mice
are insensitive to morphine yet respond to fentanyl, heroin,
methadone, and morphine-6b-glucuronide [16].
Of the three opioid receptor subtypes mu (m), delta (d) and
kappa (k), m undergoes extensive alternative splicing. The human
OPRM1 gene encoding the m receptor has 12 exons with expression
driven by two independent promoters. Alternative splicing varies
both the number of transmembrane (TM) domains (with 1, 6, or 7
TM domains), and the length and sequence of the N and C termini,
and includes exon inclusion and/or skipping, alternative 30 splice
selection, and intron retention (Fig. 1) [17].
The most obvious way in which m receptor alternative splicing
might regulate function is in response to opiate analgesics, most of
which are targeted to the m receptors, and this is indeed the case
[17]. Exon-targeted disruption within OPRM1 has identifiedATG
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FIGURE 2
Alternative splicing of the human mu opioid receptor, MOR-1. MOR-1 is extensive
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sites and exon structure, and examples of different splice variants protein structures
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Source: Adapted from [123].regions critical for analgesia produced by different opiates; for
example, morphine requires the inclusion of exons 1, 2, and 3.
Isoforms excluding exon 1 are not inhibited by morphine, but are
activated by the heroin metabolite, 6-acetylmorphine and mor-
phine-6b-glucuronide, although with a reduced potency [18].
Novel molecules that target the 6TM domain truncated variant
MOR have been described as potent analgesics, with no respiratory
depression, dependence, or rewarding effects (Fig. 2), and analge-
sia can be rescued in m receptor-knockout (KO) mice with these
truncated forms [19]. Alternative splice variants are also associated
with differences in opioid dependence [20] and morphine toler-
ance [21]. Thus, understanding m receptor alternative splicing has
already been shown to be important in understanding opiate
pharmacology and in the development of new analgesics.
In other areas, the effects of m receptor splicing are not yet clear.
Alternative splicing of the m opioid receptor can affect regional and
cellular expression, and the engagement of intracellular signaling
pathways. m opioid receptor splice variants are regionally distrib-
uted in the central nervous system (CNS), with mMOR-1C being
predominant in the thalamus, mMOR-1D abundant in the cortex,
brain stem, and periaqueductal grey, and mMOR-1E predominant
in the striatum and hypothalamus [5]. Given the different phar-
macology, such regional distributions could underlie observed5
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vomiting.
In the superficial laminae of the dorsal horn, m variants contain-
ing exons 7, 8, or 9, and, hence, different intracellular C termini,
are localised to presynaptic terminals expressing CGRP, whereas
exon 4-containing variants are expressed equally across pre- and
postsynaptic neurons, but not in CGRP-expressing neurons [22].
Alternative splicing varies the length of the m opioid mRNA 30
untranslated region (UTR) and the translated 30 tail from that of
two amino acids in mMOR-1B5 to 88 amino acids in mMOR-1U.
The C termini of m receptors contain the protein kinase sites b-
adrenergic receptor kinase, protein kinase C, cAMP- and cGMP-
dependent protein kinase, and casein kinase II [17]. Thus, alterna-
tive splicing in the m opioid 30 UTR is likely to affect the processing,
localisation, and interactions of both the message RNA and the
translated protein, in turn regulating receptor function.
Metabotropic glutamate receptors
All metabotropic glutamate receptors (mGluR1–8) except mGluR2
are reported in the literature to have expressed splice variants,
although genome database interrogation suggests that mGluR2
also has alternative spliced transcripts. Differential splice variant
expression of group I mGluRs (mGluR1 and 5) has been identified
in the dorsal horn [23]. The human gene encoding mGluR1 has at
least four C-terminal splice variants with varying pharmacological
properties and a dominant-negative truncated isoform containing
the extracellular ligand-binding domain without the canonical
7TMDs [24]. Other truncated mGluRs, also predicted to lack the
7TMDs, have been reported and some of these are postulated to act
as secreted soluble receptors or dominant-negative isoforms.
A knock-in mutant of the mGluR7 splice variant mGluR7a that
lacks the PDZ domain showed impaired PKC-dependent autoin-
hibition of glutamate release, spatial working memory deficits,
and increased susceptibility to pentylenetetrazole, but no effect on
pain behaviour or anxiety was observed, indicating that the cor-
rect function of this isoform is not required for normal nociceptive
processing [25]. Besides this study, little is known about how
differential isoform and consequent domain expression of mGluRs
in the CNS affects pain processing and pain states. Promoting the
generation of dominant-negative mGluR isoforms over fully func-
tional receptors or vice versa, depending on the mGluR subtype in
question, could be an alternative analgesic strategy to receptor
activation and/or antagonism or allosteric modulation.
Cannabinoid receptors
Two cannabinoid receptors have been identified to date, CB1 and
CB2, and nonselective CB receptor agonists can reduce pain
sensitivity in humans and animal models [26]. There are three
CB1 alternative splice variants with varying N terminal sequences.
Initial investigations suggest that CB1 splice variants have differ-
ent pharmacological properties in response to endocannabinoids
or synthetic ligands [27], but how these differences might impact
pain relief and the unwanted psychoactive adverse effects from
cannabinoids is unknown.
In normal physiology, CB2 is expressed at a lower level than CB1
in the CNS. In experimental models of neuropathic and inflam-
matory pain, CB2 expression is induced in spinal microglia, peri-
vascular cells, and C-fibre primary afferents [28]. CB2 agonists can1790 www.drugdiscoverytoday.cominhibit associated pain behaviours [29]; thus, CB2 is an attractive
target for the treatment of chronic pain. The human CB2 gene has
two reported splice variants generated through tissue-specific
promoter use. CB2A mRNA is detected at a higher level in brain
than is CB2B, which is predominantly expressed in spleen and
peripheral tissues [4]. Controlling the splicing could enhance CB2
expression in desired tissues and/or cells, while suppressing ex-
pression in cells and/or tissues where CB2 activation might have
adverse effects, for example to favour primary afferent or dorsal
horn spinal neuron expression in peripheral neuropathic pain
states.
Serotonin receptors
Fifteen genes encode seven serotonin subfamilies (5HT1–5HT7)
classed on pharmacological properties, amino acid sequences,
gene organisation, and second messenger coupling pathways.
Six of the subfamilies are GPCRs and splice variants are reported
for all families [30]. Serotonergic pathways are important in the
descending modulation, both inhibitory and facilitatory, of spinal
nociceptive processing [31].
The serotonin receptor 2C (5HTR2C) splice variants have re-
ceived more attention than other 5HT receptors because, in addi-
tion to exon 5b skipping producing mRNA species containing
exon 5a with or without 5b and an inactive truncated form of
5HTR2C [32], 5HTR2C is subject to further RNA editing in the form
of base conversions (such as adenosine to inosine, and others).
These conversions also have an effect on the splicing events. Fully
unedited mRNA generates a constitutively active 5HTR2C isoform
that can function without the presence of serotonin, whereas
inefficient RNA editing leads to increased exon 5b skipping, there-
by promoting the generation of the inactive form. 5HTR2C con-
tributes to endogenous analgesia in the dorsal horn in neuropathic
pain states, and splicing and/or RNA editing of this receptor under
these conditions seems to favour those splice variants with the
highest agonist-independent and agonist-induced activity [33].
Gamma-aminobutyric acid type B receptors
Gamma-aminobutyric acid type B (GABAB) receptor splice variants
show differential expression patterns in the CNS [34] GABAB
receptor agonists, such as baclofen, are used to treat alcohol
dependency, muscle spasms and spasticity, and neuropathic pain.
Chronic alcohol abuse leads to aberrant splicing of the GABAB
ligand-binding subunit (GABAB1) in the prefrontal cortex [35],
which is postulated to reduce GABAB receptor function in response
to ligand, increasing the dose of agonist required in the clinic for
effective treatment. It is unknown whether the splicing of GABAB
receptor is altered in other painful neuropathies.
Adrenergic receptors
Alpha-adrenergic receptor (a-AR) agonists, such as clonidine, are
well known for having analgesic and anaesthetic qualities, and
beta-adrenergic receptors (b-AR) are also promising therapeutic
targets for pain management because b2-AR isoforms are expressed
by primary afferent neurons within the dorsal horn of the spinal
cord and are critical for the antinociceptive actions of antidepres-
sant drugs [36]. However, of all the adrenergic receptors, only the
genes encoding a1-AR and b3-AR [37,38] contain introns enabling
alternative splicing, which in the case of b3-AR affects G-protein
Drug Discovery Today  Volume 21, Number 11 November 2016 REVIEWS
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ing affects the antinociceptive properties of adrenergic receptor
pharmacology remains unexplored.
Prostaglandin E2 EP3 receptors
Prostaglandin E2 (PGE2) is synthesised by cyclooxygenase and can
facilitate pain processing through four prostaglandin E2 receptors
(EP1–4), of which only the EP3 subtype has alternative splice
variants [39]. In the periphery, PGE2 affects neuronal excitability
through EP1, EP3, and EP4 receptors and also modulates central
nociceptive processing. Alternative EP3 splice variants differ in
their C-terminal sequences, which affects both downstream sig-
naling through either excitatory or inhibitory G proteins, and
receptor internalisation [40]. For example, EP3a activation, an
inhibitory G protein-coupled splice variant, can reduce both me-
chanical stimulus sensitivity and PGE2-induced spinal neuron
excitability [41]. Unfortunately, little is known about the different
contributions of EP3 receptor splice variants (as opposed to the EP
subtypes) to nociception and how they might be exploited to, for
example, reduce the adverse effects associated with current clinical
cyclooxygenase inhibition.
Ion channels, alternative splice variants, and pain
VGCCs
The contributions of VGCC to nociception and other functions
have been comprehensively reviewed many times (e.g., [42]); thus,
we provide here overview of selected splice variants of Cav channel
alpha subunits that have been particularly associated with noci-
ception/pain. Ten Cav genes encode the pore-forming alpha sub-
units of the Cav channels, with potentially thousands of splice
variants giving rise to a huge number of calcium channels. The
different alpha subunit splice variants confer different properties
in the channels, through different tissue localisations and/or
channel properties [43].
High VGCCs require strong depolarisation of cells to be activat-
ed. Of the many different Cav types, the high voltage L, N, P/Q, and
R types have been implicated in the neuronal processing of noci-
ception. The majority of these Cav types are known to have splice
variants, particularly the N and R types that confer different
properties on nociceptors [44]. The alpha subunits Cav2.1 [P/Q
(Purkinje/granule cell)-type], Cav2.2 [N (neuronal) type] and
Cav2.3 [R (toxin-resistant) type] are all expressed in sensory neu-
rons and contribute to the presynaptic control of neurotransmitter
release from nociceptive primary afferents, and the postsynaptic
activation of spinal neurons.
Cav2.2 (N-type) VGCC
The N-type calcium channel Cav2.2 is expressed on the central [45]
and peripheral [46] terminals of the peptidergic group of nocicep-
tive primary afferents and controls the release of the excitatory
neurotransmitter and/or modulators glutamate and substance P.
The splice variants of N-type calcium channels have been studied
in great depth over several years, particularly with respect to the
alternatively spliced exons (E)37a and b, and the effects that the
inclusion of E37a or E37b have on channel properties and cellular
events.
N-type calcium channels are subject to inhibition by GPCR-
dependent pathways, for example, activation of presynapticm opioid receptors inhibits the opening of Cav2.2, thereby reduc-
ing the release of neurotransmitter [47]. The alternative splicing of
the mutually exclusive exons 37a or 37b leads to two characterised
Cav2.2 isoforms that differ by 32 amino acids at the C terminus.
The E37a variant is enriched in nociceptive afferents, has higher
expression levels on the cellular membrane, increases current
density, and has longer opening times [48]. Cav2.2E37a is also
subject to stronger inhibition by activation of presynaptic opioid
[49] and GABA receptors compared with the E37b isoform, which
is voltage independent. Thus, this alternative splicing of Cav2.2
renders nociceptive afferents more sensitive to modulation by
GPCRs and, hence, controls the sensitivity of neurotransmitter
release from these neurons at their first spinal synapse. This is
important for pain because non-isoform-selective pharmacologi-
cal inhibitors of Cav2.2 (e.g., w-conotoxin MVIIA; a.k.a. zicono-
tide) can block both inflammatory and neuropathic pain in animal
models [50]. However, nerve injury and inflammation variably
reduce [51,52] or increase [53] the expression and/or function of
Cav2.2 channels, contributing to the generation of chronic pain in
addition to affecting the actions of spinally acting analgesics that
modulate Cav2.2 subunits [54]. The generation of isoform-specific
pharmacological tools could lead to more effective pain control
through direct Cav2.2 blockade or possibly through the potentia-
tion of opioid analgesia.
Calcium channel beta and alpha2delta subunits
The a2d calcium channel subunits have generated a large amount
of interest as the target of gabapentin, an analgesic used in the
treatment of neuropathic pain. At least two of the a2d subunit
family, a2d-1 and 2, have multiple splice variants [55]. a2d sub-
units are thought to contribute to the trafficking and function of
Cav2.2 under nerve injury conditions, and are necessary for the
development of neuropathic pain [56]. There are five reported
splice variants of a2d-1bin sensory neurons, two of which,
DA + B + C and DA + BDC, are upregulated in injured neurons
following traumatic injury [57]. These both form functional calci-
um channels with similar properties, but the shorter form has
lower binding affinity for gabapentin. The authors speculate that
the variable patient response to gabapentin might be related to
altered expression levels of this particular splice variant. Gabapen-
tin can also exert its effects on calcium channel trafficking through
binding of a splice variant of the beta4 subunit [58]. There are four
beta subunit genes, each of which also has splice variants [59]. The
function and possible relevance to nociception of other beta
subunit splice variants are not currently known.
R-type (Cav2.3), L-type (Cav1.1–1.4), and P/Q-type (Cav2.1) VGCC
There are six known splice variant isoforms of Cav2.3 [60]
(Cav2.3a–f). Cav2.3e is the major isoform expressed in spinal
and trigeminal sensory neurons, being found largely in the noci-
ceptive TrkA-expressing subgroup [60], where it also contributes to
the control of spinal neurotransmitter release [61]. Pharmacologi-
cal blockade of Cav2.3 has implicated these channels in spinal
nociceptive processing, particularly in neuropathic pain [51] and
opiate analgesia [62]. Cav1 and Cav2 channels are important in the
regulation of membrane excitability, and are extensively spliced,
but there are no studies that show any clear association between
L-type (Cav1.1, 1.2, 1.3, and 1.4) or P/Q-type (Cav2.1) calciumwww.drugdiscoverytoday.com 1791
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familial hemiplegic migraine [63].
The large family of proteins that together comprise calcium
channels is notable for having many splice variants. Although
some of these splice variants have been characterised, we are still a
long way from a full understanding of how pain states might affect
calcium channel splicing, or how different calcium channel sub-
unit splice variants might affect nociceptive processing. However,
these examples show how understanding splice variant function
can further the development of pharmacological approaches to
pain control.
Voltage-gated sodium channels
Voltage-gated sodium channels (VGSC) are major determinants of
neuronal excitability, determining the depolarisation phase (up-
stroke) of the action potential. Similar to VGCC, VGSC comprise
different subunits: the pore-forming alpha subunit, and one or
more beta subunits. Mutations in certain VGSC are now known to
cause pain syndromes, congenital insensitivity to pain, or neurop-
athies [6]. The VGSC are usually considered in two groups, the
tetrodotoxin (TTX) sensitive (Nav1.1–1.4, Nav1.6, and Nav1.7) and
the TTX resistant (Nav1.5, Nav1.8, and Nav1.9). Alternative splice
variants of both TTX-sensitive and -resistant groups have been
reported, but the functional consequences have been described for
only a few of these splice variants [64,65].
Nerve injury results in the downregulation of most VGSC,
except for Nav1.3, which is upregulated [64,65]. The upregulation
appears to be limited to the originally described transcript rather
than to a longer form also found in DRG, containing an additional
exon [64]. The expression of Nav1.7, 1.8 and 1.9 channels is largely
restricted to sensory and autonomic peripheral neurons, and
Nav1.8 and 1.9 are further restricted to small and medium DRG
neurons, the majority of which have nociceptive properties.
Alternative splice variants of Nav1.7 are generated by the mu-
tually exclusive alternative splicing of exons in human, rat, and
mouse. The control of splicing is altered in nerve injury, under
which conditions the exon11RS-containing transcripts increase in
abundance [65]. Alternative splicing in specific regions of Nav1.7
can affect channel properties, such as inactivation and/or reacti-
vation or ramp current properties [66]. In Nav1.7 containing a
paroxysmal extreme pain disorder mutation (I1461T), multiple
properties are altered, including activation, inactivation, closed-
state inactivation, and ramp current responses, resulting in
increases in numbers of channels available for activation and open
probability in these patients [66]. Alternative splice site selection
results in the generation of a variant of Nav1.8 in DRG neurons
[64,67], with no reported effect of the alternative splicing on
channel function [67].
Gain-of function mutations in Nav1.7 and 1.9 result in the
inherited pain syndromes erythromelalgia [6], paroxysmal ex-
treme pain disorder [66], autosomal-dominant episodic pain
[68], and small-fibre neuropathies [6]. Loss-of-function mutations
result in congenital insensitivity to pain [69]. Small-fibre neurop-
athy and congenital insensitivity to pain are also associated with
variants of Nav1.8 and 1.9, respectively [69]. Some of the known
mutations in VGSC in these conditions have been reported to
affect splice sites [67]; therefore, alternative splicing is also likely to
contribute to such pain syndromes in humans.1792 www.drugdiscoverytoday.comPotassium channels
Potassium channels form the largest ion channel family, and are
fundamental to the control of neuronal excitability and the func-
tion of multiple cell types. Mutations of potassium channels have
profound effects on function, and have been associated with many
different conditions and/or diseases, such as epilepsy, ataxia,
deafness, hypertension, and hyperinsulinemic hypoglycemia,
among many others [70]. There are many different families of
potassium channels, including voltage gated, calcium-activated,
inwardly rectifying, two-pore, and hyperpolarisation and cyclic
nucleotide-activated channels [70]. Although alternatively spliced
potassium channels are both predicted and known to exist, con-
sidering the diversity of this family, and the important processes in
which these channels are involved, it is perhaps surprising that
there are many fewer reports of alternative splicing in this family
compared with calcium and sodium channels, and none with
specific reference to pain and/or nociception [71,72].
Some of the most likely candidates for study are the two-pore
potassium channels, which are expressed in peripheral nociceptive
neurons and have been implicated in thermal mechanical and
chemical nociception [71]. Splice variants of this family have been
described, including N-terminal variants of TREK-1, TREK-2, and
TRAAK, and truncated versions of TREK-1 and TRAAK. The trun-
cated TREK-1 and TRAAK channels exert dominant negative
effects, form nonfunctional channels, or alter cell surface receptor
number; thus, control of splicing in favour of these variants could
have therapeutic value [71,72].
Transient receptor potential channels
Many transient receptor potential (TRP) channels have been wide-
ly studied in relation to somatosensation and pain. The archetypal
TRP channel, TRPV1 (a.k.a. the capsaicin receptor) was the first
mammalian TRP channel to be cloned, and is intimately related to
nociceptive systems, because, in the DRG, it is expressed almost
predominantly in nociceptive sensory afferents [73]. It not only
transduces noxious heat in sensory afferents, but also interacts
with other TRP channels, specifically TRPA1, to sensitise nocicep-
tive afferent terminals to multiple stimuli [74]. Other TRP chan-
nels have subsequently been identified and localised to sensory
afferents, and are involved in cool and/or noxious cold sensation
(TRPM8), warm sensation (TRPV3), mechanical nociception
(TRPV4), and very high threshold noxious heat (TRPV2). TRP
channels, particularly TRPV1 and TRPA1, are under intensive
study as potential drug targets for analgesics [75]. There has been
a relatively recent review of the splicing controls of the whole TRP
superfamily [76]; thus, here we concentrate only on those chan-
nels with particularly well-defined functions of splice variants in
nociception: TRPV1 and TRPA1.
Of the four TRPV1 splice variants, three are expressed in DRG or
trigeminal ganglia and have some involvement in nociceptive
processing [77]. Splicing affects the N-terminal domain in all these
splice variants, resulting in loss of activation by capsaicin (in
human TRPV1b and TRPV1b[77]) and by other activators, such
as protons, resiniferatoxin, and temperature (VR1 5’sv [78]), or can
render the channel as a dominant negative (TRPV 5’sv, TRPV1b
[79]). These splice variants have functional responses that are
different from full-length TRPV1 [79], as might be predicted.
When co-expressed with full-length TRPV1, TRPV1 5’sv reduces
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duction in channel expression, or destabilisation of heteromeric
channels [79].
TRPA1 channels are largely co-expressed, and can interact, with
TRPV1 channels in nociceptors [74]. TRPA1 channels have been
referred to as universal sensitiser molecules, because they act to
sensitise nociceptors to multiple stimuli. One TRPA1 splice variant
has been described; this channel alters the cell surface expression
of full-length TRPA1 and, when co-expressed with the full-length
channel, increases responses to ligand activation. The transcript
for this splice variant is regulated in chronic pain states, such as
inflammatory and neuropathic pain, suggesting that it contributes
to altered neuronal function in these conditions [80].
Ionotropic glutamate receptors
There are eight splice variants of the NR1 subunit of the NMDA
receptor [81]. Inclusion of exons 5 and 21 within the NR1 subunit
of the receptor is repressed by a depolarisation-induced Ca2+/
calmodulin protein kinase (CaMK) pathway, by activation of a
sequence known as a CaMK IV-responsive RNA element [11].
Inclusion of exon 5 (NR1-1b variant) reduces the affinity of NR1
for both glutamate and NMDA and potentiates receptor function
[81]. Inclusion of exon 21 (NR1-3b) confers calmodulin sensitivity
on the resultant channel, binding of which inhibits channel
activity [82]. As a result, all of these variants could have signifi-
cantly different functions compared with other isoforms.
Splice variants including exons 5, 21, and 22 (NR1-1b, NR1-3b
and NR1-4b variants respectively) are expressed in the dorsal horn
of the spinal cord [83], as is the NR1-4a variant, which is coloca-
lised with NK1 receptors [84]. NK1-expressing neurons in the
dorsal horn are nociceptive projection neurons, suggesting that
these splice variants are associated with nociceptive processing.
Although splicing to NR1-3b is suppressed [11] by neuronal depo-
larisation, enhanced nociception induced with formalin was not
associated with changed expression of any NR1 splice variant [85].
Acid-sensing ion channels
There are four acid-sensing ion channels (ASIC): ASIC1, ASIC2
(previously MDEG), ASIC3 (previously DRASIC) and ASIC4 (previ-
ously SPASIC), some of which have splice variants (ASIC1a/b,
ASIC2a/b). ASICs are found in the central (ASIC1a and ASIC2a
and b) and peripheral (ASIC1a and b, 2a and b, 3 and 4 [86])
nervous systems in rodents [87]. ASIC channels are fundamentally
important in inflammatory pain in both humans and rodents,
because they are expressed in somatic and visceral nociceptors,
and are activated by low pH [87]. ASIC channels are also expressed
in many muscle afferents, implying that they detect metabolic
changes, for example, resulting from exercise, and signal pain on
tissue acidosis [87]. Given the expression over a large diameter,
presumed low threshold sensory afferents, and in nerve endings
innervating hair follicles, ASICs have also been hypothesised to
have a mechanosensitive function, although this is still under
debate [87]. The exact function(s) of ASICs in the CNS are not yet
known, but they are also expressed in nociceptive pathways and
contribute to opioid analgesia [87].
ASIC1a and ASIC1b differ functionally in that ASIC1b is imper-
meable to calcium ions [88]; other channel properties are similar
between the two splice variants [89]. ASIC2a and 2b differ in thatthere is an additional transmembrane domain in the N-terminal
region of ASIC2b. ASIC2b, which is not activated by protons [90],
can form heteromers with both ASIC2a and ASIC3, resulting in
channels with more slowly inactivating properties, higher peak
currents (with ASIC2a), and channel nonselectivity in the late
prolonged phase (with ASIC2a and ASIC3). These sustained cur-
rents resulting from heteromers of splice variants might function-
ally determine nociceptive neuronal responses to sustained low
pH, such as in inflammatory conditions.
P2X receptors
P2X receptors are a family of seven ATP-gated ion channels (P2X1–
P2X7), formed from three subunits. In humans, the P2X5 is
nonfunctional as a result of a splicing event that removes exon
10; if the exon is replaced, or in humans with a polymorphism in
which the necessary intronic splicing site is maintained, the
channel regains function [91]. Described P2X variants can have
alterations in different regions, some of which are involved in
interaction with other proteins, including other P2X subunits, and
control of ion permeability [92]. Therefore, P2X splice variants
would be predicted to have different functional properties, such as
differences in desensitisation [93] or affinity for ATP [94], although
others show no obvious difference in functional or pharmacologi-
cal properties.
The function of many of the P2X receptors has been inferred by
expression analysis and phenotypic analysis of mouse KO lines.
From these studies, the P2X receptors most strongly implicated in
nociception are P2X2, P2X3, P2X4, and P2X7. There is as yet little
published evidence of a role for specific splice variants of these four
subunits in nociception, other than those of the P2X7 receptor.
This is perhaps surprising given the importance of P2X2/3 recep-
tors for the function of primary afferent nociceptors [95].
The role for the P2X7 in nociception, particularly in mecha-
nisms of central sensitisation, is widely recognised, in part as a
result of the use of KO mice that showed deficiencies in neuro-
pathic and inflammatory pain behaviours [96]. A recent study on
bone cancer pain showed that P2X7 KO mice exhibited more
severe pain behaviours than wild-type mice, and expressed the
P2X7(k) splice variant in the spinal cord [97]. The P2X7 antagonist
A-438079 had no effect on pain behaviours in these animals [97].
The P2X7(k) splice variant has a higher sensitivity to ATP than the
‘classical’ P2X7(a) receptor, and shows sensitivity to ADP-ribosyla-
tion not seen in the P2X7(a) variant. The authors concluded that
the presence of the P2X7(k) splice variant was unlikely to result in
maintained and/or enhanced pain in these animals, because of the
use of the same animals to define the important function of P2X7
in chronic pain [97]. Given the different functional properties of
the splice variant, it is difficult not to speculate that the P2X7(k)
variant could have an, as yet, undefined role in spinal nociceptive
processing or in determining pharmacological responses.
GABAA receptors
The regulation of GABAA receptors contributes to altered nocicep-
tive processing in many experimental pain states [98]. GABAA
receptors are highly complex multimeric channels, containing
up to 14 subunit types known to contribute to these receptors.
The most common variant is the a1b2g2 type [99]; the gamma
subunit confers benzodiazepine responses on GABAA receptors.www.drugdiscoverytoday.com 1793
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FIGURE 3
Alternative splicing of the vascular endothelial growth factor A (VEGFA) gene.
(a) Structure of the VEGFA gene, showing translational start (denoted by
arrow in exon 1) and stop codons, VEGF receptor binding sites, and heparin
and neuropilin binding sites. (b) Splice variant families of the VEGF-A gene:
VEGFxxxa and VEGFxxxb. The site of the stop codon is shown only in VEGF-
A206a and b but is in the corresponding location for the other members of
each splice variant family. The angiogenic, algesic isoforms of VEGF-Axxxa are
shown on the left, and the VEGF-Axxxb antiangiogenic, analgesic isoforms on
the right. Selection of the proximal splice site in exon 8 results in the inclusion
of exons 8a and 8b, and use of the proximal stop codon in exon 8a, resulting
in a family of splice variants with the C terminal sequence CDKPRR. Use of the
distal splice site results in the inclusion of only exon 8b, and thereby
introduces a frame shift and use of the different stop codon in exon 8b. The
family of splice variants that contains exon 8b has the C terminal sequence
SLTRKD. Note that each family comprises several members, all of which
contain binding sites for both VEGFR1 and VEGFR2, but which have variable
heparin and neuropilin binding. For example, VEGF-A121a binds neither
heparin nor neuropilin, whereas VEGF-A165a binds both heparin and
neuropilin. VEGF-A165b heparin binding is less than for VEGF-A189a but
greater than for VEGF-A145a because of the differences in exon 6 splicing. (c)
There is one report in the literature of a further splice variant of VEGF-A, VEGF-
Ax, which contains exons 8a and 8b but exhibits translational read-through
and, thus, uses the 8b stop codon. Therefore, VEGF-Ax has the VEGF-Axxxb C
terminal sequence and antiangiogenic activity [124].
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2 subunits were described many years ago [100,101], nothing
has been subsequently published on their possible differential
contributions to nociceptive processing. This is surprising consid-
ering the importance of GABAA receptors to presynaptic inhibi-
tion. GABAA subunit splice variants might confer different
properties on the resultant GABAA receptors, for example the short
form of the gamma subunit g2S lacks an additional protein kinase
C (PKC) site found in the long form g2L [100]. In sensory neurons,
GABAA channel activity can be strongly modulated by PKC and,
hence, presynaptic inhibition can be enhanced or reduced. There-
fore, the presence of g2L in primary afferent nociceptors or spinal
neurons could have significant effects on spinal nociceptive pro-
cessing.
Growth factors
Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF-A) was not widely
recognised for its actions on nociceptive systems until relatively
recently [102]. This growth factor is extensively alternatively
spliced into two families of splice variants [103]: VEGF-Axxxa
and VEGF-Axxxb (Fig. 3), which have actions on multiple cell
types, particularly endothelial cells and neurons. However, many
studies overlook the presence of the VEGF-Axxxb isoforms despite
the observation that they predominate in most normal tissues.
Early studies on VEGF-A gave conflicting evidence of its actions
on nociceptive processing, with reports of both pro- and anti-
nociceptive effects. This is explained by recent work showing that
the two families have algesic (VEGF-Axxxa) and analgesic actions
(VEGF-Axxxb) on peripheral [102,104] and central nociceptive
neurons [105].
Brain-derived neurotrophic factor
The BDNF gene has an unusual splicing pattern in that the 22
described splice variants all generate the same BDNF peptide
(Fig. 4). In the case of BDNF, the different splice variants contribute
to the control of BDNF expression by differential regulation in
different areas of the brain or in other tissues, such as skeletal
muscle [8]. In inflammatory pain, only transcripts containing
exons 1, 2a, b, c, and 3 increased in primary sensory neurons
[106] (Fig. 4). These transcripts, particularly those containing exon
1, are rapidly increased by nerve growth factor (NGF) in culture,
suggesting that this potent algesic growth factor exerts effects
through control of BDNF differential splicing.
Nerve growth factor
Both NGF and its receptor TrkA have splice variants [107,108]. The
TrkA slice variants do not seem to differ in their functional
responses [108] and, surprisingly, there is no published literature
relating to different actions of known NGF splice variants in
nociception.
Targeting alternative splicing as a therapeutic strategy
Although alternative splicing has been considered as a potential
therapeutic in pathologies such as cancer, eye disease, inherited
diseases, such as spinal muscular atrophy, and viral infection [109–
112], to date few clinical trials based on the therapeutic control of
alternative splicing have been reported [113,114]. Further trials are1794 www.drugdiscoverytoday.comreportedly in progress for cholangiocarcinoma (NCT02128282,
clinicaltrails.gov), and spinal muscular atrophy (NCT02240355,
clinicaltrials.gov). As this review highlights, understanding of
alternative splicing and its therapeutic targeting should not be
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FIGURE 4
Alternative splicing of the brain-derived neurotrophic factor (BDNF) mRNA.
BDNF splicing is unusual in that, although there are at least 22 differently
spliced transcripts, all generate the same final peptide. There are at least
noncoding 50 exons (1–8) and a short noncoding sequence in exon 9 (9a) that
that can be differentially spliced at the 5-end of the mRNA. In addition, there
are three alternative splice sites in exon 2 (denoted by the different shades of
blue). The 3-coding exon 9 contains two alternative poly-adenylation sites in
exon 9 (denoted by A). The coding sequence (shown in orange) is found in all
splice variants. The translation start site (ATG) is denoted by a vertical arrow.
At least nine different promoters are present in the BDNF gene, and final
expression level, regional or subcellular site(s) of expression of BDNF peptide
is controlled by differential expression of the different splice variants.
Redrawn from [8].
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divergent areas such as physiological processes, pathology, and
regional drug differences or adverse effects. Importantly, alterna-
tive splicing, as opposed to constitutive splicing, could be an
untapped therapeutic approach in areas such as nociception
and/or pain, and neuroprotection [102,105,115].
Over the past 13 years, several strategies for the control of
alternative splicing have been suggested, including targeted oli-
gonucleotides against splice sites [116], or targeting splice factors,
such as SR proteins [117].
Chemically modified oligonucleotides resistant to degradation
have proved effective at inducing either exon skipping or blocking
splice sites in animal models and in some clinical trials, with the
aim of repair of defective mRNAs [118]. This approach can result in
the restoration of functional protein in conditions such as Duch-
enne muscular dystrophy, where splicing events result in non-
functional dystrophin. There has been some minor success in a few
clinical trials using this approach. Alternatively, oligonucleotidescan be targeted to block aberrant splicing events, restoring func-
tional protein, such as in developing approaches to treat spinal
muscular atrophy and beta-thalassemia [118]. Theoretically, these
approaches can also be used to control alternative splicing by
blocking alternative splice sites to direct splice variant expression;
there has been some reported success in this area in animal
models [119].
The SR family comprises around 40 proteins that can control
multiple steps in RNA processing, including the recognition of
splice sites, the binding of RNA polymerase II, mRNA export to the
cytoplasm, and translation control [120]. Targeting of CDC-like
kinases (Clks) and serine-arginine protein kinases (SRPKs) with
small-molecule inhibitors is emerging as a potential therapeutic
strategy because these molecules might control limited down-
stream splicing events, reducing the possibility of off-target or
other adverse effects [121]. Proof-of-principle studies have shown
efficacy in either blocking exon skipping and enhancing read-
through of full-length protein [111], or controlling alternate exon
inclusion [122], showing that these strategies might be of use in
control of, for example, congenital gain, or loss of function of
sodium channels implicated in pain states. Unfortunately, our
current understanding of the specific molecules controlling the
alternative splicing of specific mRNAs, such as sodium channels, is
limited.
The power of controlling alternative splicing is obvious. Splic-
ing directed towards truncated receptors that act as dominant-
negative isoforms could be an alternative to antagonists and/or
blockers that could reduce adverse effects. Favouring the expres-
sion of specific opioid receptor variants could potentiate the
analgesic response to an agonist. If directed to ion channels that
enhance opioid analgesia, it could improve efficacy of existing
drugs. Where families of isoforms exist that have opposite func-
tions, such as VEGF-A, control of splicing between families could
shift the balance of isoforms to affect, for example angiogenesis in
solid tumours or pain.
To target alternative splicing therapeutically, without affecting
constitutive splicing, we need a greater understanding of the
specific mechanisms through which alternative splice site selec-
tion is controlled for key pre-mRNAs. There have been significant
advances in this area, driven largely by the cancer field, but it is an
area ripe for development for novel applications, such as the
control of pain.
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